Do analysts prefer ISPC or BNGO?

Bionano Genomics has a consensus target price of $6.00, indicating a potential upside of 400.00%. Given Bionano Genomics' stronger consensus rating and higher probable upside, analysts clearly believe Bionano Genomics is more favorable than iSpecimen. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score iSpecimen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Bionano Genomics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is ISPC or BNGO more profitable?

Bionano Genomics has a net margin of -106.58% compared to iSpecimen's net margin of -2,445.40%. Bionano Genomics' return on equity of -78.78% beat iSpecimen's return on equity. Company Net Margins Return on Equity Return on Assets iSpecimen -2,445.40% -524.39% -140.42% Bionano Genomics -106.58% -78.78% -48.54%

Do analysts prefer ISPC or BFRG?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score iSpecimen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Bullfrog AI 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is ISPC or BFRG more profitable?

Bullfrog AI has a net margin of 0.00% compared to iSpecimen's net margin of -2,445.40%. Bullfrog AI's return on equity of -150.36% beat iSpecimen's return on equity. Company Net Margins Return on Equity Return on Assets iSpecimen -2,445.40% -524.39% -140.42% Bullfrog AI N/A -150.36% -127.98%

Do analysts rate ISPC or VIVS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score iSpecimen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 VivoSim Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, ISPC or VIVS?

iSpecimen has higher revenue and earnings than VivoSim Labs. VivoSim Labs is trading at a lower price-to-earnings ratio than iSpecimen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio iSpecimen $466.30K 8.32 -$10.49M -$56.44 N/A VivoSim Labs $130K 35.50 -$13.84M -$4.47 N/A

Is ISPC or VIVS more profitable?

iSpecimen has a net margin of -2,445.40% compared to VivoSim Labs' net margin of -11,016.07%. iSpecimen's return on equity of -524.39% beat VivoSim Labs' return on equity. Company Net Margins Return on Equity Return on Assets iSpecimen -2,445.40% -524.39% -140.42% VivoSim Labs -11,016.07% -612.23% -177.02%

Does the media prefer ISPC or VIVS?

In the previous week, VivoSim Labs had 2 more articles in the media than iSpecimen. MarketBeat recorded 3 mentions for VivoSim Labs and 1 mentions for iSpecimen. iSpecimen's average media sentiment score of 0.63 beat VivoSim Labs' score of 0.35 indicating that iSpecimen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iSpecimen 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive VivoSim Labs 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer TBIO or ISPC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telesis Bio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 iSpecimen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, TBIO or ISPC?

iSpecimen has lower revenue, but higher earnings than Telesis Bio. iSpecimen is trading at a lower price-to-earnings ratio than Telesis Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telesis Bio $225.09M 0.00 -$47.72M -$20.52 N/A iSpecimen $466.30K 8.32 -$10.49M -$56.44 N/A

Is TBIO or ISPC more profitable?

Telesis Bio has a net margin of -336.59% compared to iSpecimen's net margin of -2,445.40%. Telesis Bio's return on equity of 0.00% beat iSpecimen's return on equity. Company Net Margins Return on Equity Return on Assets Telesis Bio -336.59% N/A -61.89% iSpecimen -2,445.40% -524.39% -140.42%

Does the media favor TBIO or ISPC?

In the previous week, Telesis Bio and Telesis Bio both had 1 articles in the media. iSpecimen's average media sentiment score of 0.63 beat Telesis Bio's score of 0.00 indicating that iSpecimen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telesis Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral iSpecimen 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend BFRGW or ISPC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bullfrog AI 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 iSpecimen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, BFRGW or ISPC?

Bullfrog AI has higher earnings, but lower revenue than iSpecimen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bullfrog AI $298.80K N/A N/A N/A N/A iSpecimen $466.30K 8.32 -$10.49M -$56.44 N/A

Is BFRGW or ISPC more profitable?

Bullfrog AI has a net margin of 0.00% compared to iSpecimen's net margin of -2,445.40%. Bullfrog AI's return on equity of 0.00% beat iSpecimen's return on equity. Company Net Margins Return on Equity Return on Assets Bullfrog AI N/A N/A N/A iSpecimen -2,445.40% -524.39% -140.42%

iSpecimen (ISPC) Competitors

$1.54 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Compare

ISPC vs. BNGO, BFRG, VIVS, TBIO, and BFRGW

Should you buy iSpecimen stock or one of its competitors? iSpecimen's main competitors and comparable companies include Bionano Genomics (BNGO), Bullfrog AI (BFRG), VivoSim Labs (VIVS), Telesis Bio (TBIO), and Bullfrog AI (BFRGW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does iSpecimen compare to Bionano Genomics?

iSpecimen (NASDAQ:ISPC) and Bionano Genomics (NASDAQ:BNGO) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, dividends, valuation and earnings.

Bionano Genomics has a net margin of -106.58% compared to iSpecimen's net margin of -2,445.40%. Bionano Genomics' return on equity of -78.78% beat iSpecimen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iSpecimen	-2,445.40%	-524.39%	-140.42%
Bionano Genomics	-106.58%	-78.78%	-48.54%

iSpecimen has a beta of 1.62, meaning that its share price is 62% more volatile than the broader market. Comparatively, Bionano Genomics has a beta of 1.65, meaning that its share price is 65% more volatile than the broader market.

13.6% of iSpecimen shares are owned by institutional investors. Comparatively, 11.4% of Bionano Genomics shares are owned by institutional investors. 12.2% of iSpecimen shares are owned by insiders. Comparatively, 0.7% of Bionano Genomics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

iSpecimen has higher earnings, but lower revenue than Bionano Genomics. Bionano Genomics is trading at a lower price-to-earnings ratio than iSpecimen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iSpecimen	$466.30K	8.32	-$10.49M	-$56.44	N/A
Bionano Genomics	$28.51M	0.50	-$26.40M	-$3.02	N/A

Bionano Genomics has a consensus target price of $6.00, indicating a potential upside of 400.00%. Given Bionano Genomics' stronger consensus rating and higher probable upside, analysts clearly believe Bionano Genomics is more favorable than iSpecimen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iSpecimen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bionano Genomics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, iSpecimen had 1 more articles in the media than Bionano Genomics. MarketBeat recorded 1 mentions for iSpecimen and 0 mentions for Bionano Genomics. iSpecimen's average media sentiment score of 0.63 beat Bionano Genomics' score of 0.00 indicating that iSpecimen is being referred to more favorably in the media.

Company	Overall Sentiment
iSpecimen	Positive
Bionano Genomics	Neutral

Summary

Bionano Genomics beats iSpecimen on 9 of the 16 factors compared between the two stocks.

How does iSpecimen compare to Bullfrog AI?

iSpecimen (NASDAQ:ISPC) and Bullfrog AI (NASDAQ:BFRG) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, media sentiment and analyst recommendations.

In the previous week, iSpecimen had 1 more articles in the media than Bullfrog AI. MarketBeat recorded 1 mentions for iSpecimen and 0 mentions for Bullfrog AI. iSpecimen's average media sentiment score of 0.63 beat Bullfrog AI's score of 0.00 indicating that iSpecimen is being referred to more favorably in the media.

Company	Overall Sentiment
iSpecimen	Positive
Bullfrog AI	Neutral

Bullfrog AI has lower revenue, but higher earnings than iSpecimen. Bullfrog AI is trading at a lower price-to-earnings ratio than iSpecimen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iSpecimen	$466.30K	8.32	-$10.49M	-$56.44	N/A
Bullfrog AI	$120K	77.74	-$6.50M	-$0.46	N/A

iSpecimen has a beta of 1.62, indicating that its stock price is 62% more volatile than the broader market. Comparatively, Bullfrog AI has a beta of -2.71, indicating that its stock price is 371% less volatile than the broader market.

Bullfrog AI has a net margin of 0.00% compared to iSpecimen's net margin of -2,445.40%. Bullfrog AI's return on equity of -150.36% beat iSpecimen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iSpecimen	-2,445.40%	-524.39%	-140.42%
Bullfrog AI	N/A	-150.36%	-127.98%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iSpecimen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bullfrog AI	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

13.6% of iSpecimen shares are held by institutional investors. Comparatively, 1.0% of Bullfrog AI shares are held by institutional investors. 12.2% of iSpecimen shares are held by insiders. Comparatively, 14.7% of Bullfrog AI shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Bullfrog AI beats iSpecimen on 8 of the 14 factors compared between the two stocks.

How does iSpecimen compare to VivoSim Labs?

iSpecimen (NASDAQ:ISPC) and VivoSim Labs (NASDAQ:VIVS) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

In the previous week, VivoSim Labs had 2 more articles in the media than iSpecimen. MarketBeat recorded 3 mentions for VivoSim Labs and 1 mentions for iSpecimen. iSpecimen's average media sentiment score of 0.63 beat VivoSim Labs' score of 0.35 indicating that iSpecimen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iSpecimen	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
VivoSim Labs	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

iSpecimen has a beta of 1.62, indicating that its share price is 62% more volatile than the broader market. Comparatively, VivoSim Labs has a beta of 1.45, indicating that its share price is 45% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iSpecimen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
VivoSim Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

iSpecimen has higher revenue and earnings than VivoSim Labs. VivoSim Labs is trading at a lower price-to-earnings ratio than iSpecimen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iSpecimen	$466.30K	8.32	-$10.49M	-$56.44	N/A
VivoSim Labs	$130K	35.50	-$13.84M	-$4.47	N/A

iSpecimen has a net margin of -2,445.40% compared to VivoSim Labs' net margin of -11,016.07%. iSpecimen's return on equity of -524.39% beat VivoSim Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iSpecimen	-2,445.40%	-524.39%	-140.42%
VivoSim Labs	-11,016.07%	-612.23%	-177.02%

13.6% of iSpecimen shares are held by institutional investors. Comparatively, 8.2% of VivoSim Labs shares are held by institutional investors. 12.2% of iSpecimen shares are held by company insiders. Comparatively, 1.0% of VivoSim Labs shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

iSpecimen beats VivoSim Labs on 10 of the 13 factors compared between the two stocks.

How does iSpecimen compare to Telesis Bio?

Telesis Bio (NASDAQ:TBIO) and iSpecimen (NASDAQ:ISPC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability.

In the previous week, Telesis Bio and Telesis Bio both had 1 articles in the media. iSpecimen's average media sentiment score of 0.63 beat Telesis Bio's score of 0.00 indicating that iSpecimen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telesis Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
iSpecimen	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

iSpecimen has lower revenue, but higher earnings than Telesis Bio. iSpecimen is trading at a lower price-to-earnings ratio than Telesis Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telesis Bio	$225.09M	0.00	-$47.72M	-$20.52	N/A
iSpecimen	$466.30K	8.32	-$10.49M	-$56.44	N/A

Telesis Bio has a beta of 2.45, suggesting that its share price is 145% more volatile than the broader market. Comparatively, iSpecimen has a beta of 1.62, suggesting that its share price is 62% more volatile than the broader market.

37.6% of Telesis Bio shares are held by institutional investors. Comparatively, 13.6% of iSpecimen shares are held by institutional investors. 24.5% of Telesis Bio shares are held by insiders. Comparatively, 12.2% of iSpecimen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Telesis Bio has a net margin of -336.59% compared to iSpecimen's net margin of -2,445.40%. Telesis Bio's return on equity of 0.00% beat iSpecimen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telesis Bio	-336.59%	N/A	-61.89%
iSpecimen	-2,445.40%	-524.39%	-140.42%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telesis Bio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
iSpecimen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Telesis Bio beats iSpecimen on 9 of the 13 factors compared between the two stocks.

How does iSpecimen compare to Bullfrog AI?

Bullfrog AI (NASDAQ:BFRGW) and iSpecimen (NASDAQ:ISPC) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, media sentiment, analyst recommendations, risk, dividends and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bullfrog AI	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
iSpecimen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Bullfrog AI has a net margin of 0.00% compared to iSpecimen's net margin of -2,445.40%. Bullfrog AI's return on equity of 0.00% beat iSpecimen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bullfrog AI	N/A	N/A	N/A
iSpecimen	-2,445.40%	-524.39%	-140.42%

Bullfrog AI has higher earnings, but lower revenue than iSpecimen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bullfrog AI	$298.80K	N/A	N/A	N/A	N/A
iSpecimen	$466.30K	8.32	-$10.49M	-$56.44	N/A

Company	Overall Sentiment
Bullfrog AI	Neutral
iSpecimen	Positive

13.6% of iSpecimen shares are held by institutional investors. 12.2% of iSpecimen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

iSpecimen beats Bullfrog AI on 6 of the 9 factors compared between the two stocks.

Get iSpecimen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ISPC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ISPC vs. The Competition

Export

Metric	iSpecimen	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.88M	$9.94B	$7.25B	$12.91B
Dividend Yield	N/A	1.46%	2.53%	9.14%
P/E Ratio	-0.03	65.01	274.10	25.45
Price / Sales	8.32	111.84	637.63	106.01
Price / Cash	N/A	26.85	77.08	52.44
Price / Book	2.23	35.98	12.85	6.17
Net Income	-$10.49M	$56.67B	$3.49B	$350.08M
7 Day Performance	N/A	-0.83%	1.04%	-0.14%
1 Month Performance	-30.00%	4.01%	5.39%	0.94%
1 Year Performance	-95.49%	24.29%	24.18%	14.02%

iSpecimen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ISPC iSpecimen	0.4956 of 5 stars	$1.54 flat	N/A	-95.5%	$3.88M	$466.30K	N/A	60	High Trading Volume
BNGO Bionano Genomics	1.8037 of 5 stars	$1.25 +2.5%	$6.00 +380.0%	-69.9%	$14.37M	$28.51M	N/A	300	Analyst Upgrade
BFRG Bullfrog AI	0.9817 of 5 stars	$0.58 +3.2%	N/A	-55.9%	$10.42M	$120K	N/A	4
VIVS VivoSim Labs	0.2717 of 5 stars	$0.29 -0.1%	N/A	-88.9%	$4.84M	$130K	N/A	20	News Coverage Positive News
TBIO Telesis Bio	N/A	$0.00 flat	N/A	-91.7%	$2K	$225.09M	N/A	200

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ISPC) was last updated on 9/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

iSpecimen (ISPC) Competitors

ISPC vs. BNGO, BFRG, VIVS, TBIO, and BFRGW

How does iSpecimen compare to Bionano Genomics?

Summary

How does iSpecimen compare to Bullfrog AI?

Summary

How does iSpecimen compare to VivoSim Labs?

Summary

How does iSpecimen compare to Telesis Bio?

Summary

How does iSpecimen compare to Bullfrog AI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ISPC vs. The Competition

iSpecimen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

iSpecimen (ISPC) Competitors

ISPC vs. BNGO, BFRG, VIVS, TBIO, and BFRGW

How does iSpecimen compare to Bionano Genomics?

Is ISPC or BNGO more profitable?

Which has more volatility and risk, ISPC or BNGO?

Do institutionals and insiders believe in ISPC or BNGO?

Which has higher earnings and valuation, ISPC or BNGO?

Do analysts prefer ISPC or BNGO?

Does the media refer more to ISPC or BNGO?

Summary

How does iSpecimen compare to Bullfrog AI?

Does the media prefer ISPC or BFRG?

Which has stronger earnings and valuation, ISPC or BFRG?

Which has more volatility & risk, ISPC or BFRG?

Is ISPC or BFRG more profitable?

Do analysts prefer ISPC or BFRG?

Do insiders & institutionals have more ownership in ISPC or BFRG?

Summary

How does iSpecimen compare to VivoSim Labs?

Does the media prefer ISPC or VIVS?

Which has more volatility and risk, ISPC or VIVS?

Do analysts rate ISPC or VIVS?

Which has better valuation and earnings, ISPC or VIVS?

Is ISPC or VIVS more profitable?

Do institutionals and insiders have more ownership in ISPC or VIVS?

Summary

How does iSpecimen compare to Telesis Bio?

Does the media favor TBIO or ISPC?

Which has preferable earnings & valuation, TBIO or ISPC?

Which has more volatility & risk, TBIO or ISPC?

Do institutionals & insiders have more ownership in TBIO or ISPC?

Is TBIO or ISPC more profitable?

Do analysts prefer TBIO or ISPC?

Summary

How does iSpecimen compare to Bullfrog AI?

Do analysts recommend BFRGW or ISPC?

Is BFRGW or ISPC more profitable?

Which has preferable earnings and valuation, BFRGW or ISPC?

Does the media prefer BFRGW or ISPC?

Do institutionals and insiders have more ownership in BFRGW or ISPC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ISPC vs. The Competition

iSpecimen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools